Bioclinica, Inc. (BIOC) Tops Q4 EPS by 2c, Sales Beat Expectations

Bioclinica, Inc. (NASDAQ: BIOC) reported Q4 EPS of $0.09, $0.02 better than the analyst estimate of $0.07. Revenue for the quarter came in at $22.57 million versus the consensus estimate of $20.84 million.

For earnings history and earnings-related data on Bioclinica, Inc. (BIOC) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Advance Auto Parts (AAP) PT Lowered to $43 at Truist Securities
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group